By
Drug Target Review2024-06-07T10:00:56
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T13:00:00Z
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-09-22T07:00:00
Contributor Luca Lotta, By Drug Target Review
2023-02-23T14:02:18
Sponsored by bit.bio
2026-10-30T07:00:00
Contributor Dr Shi-qi An, By Drug Target Review
2026-07-10T06:15:00
Contributor Professor Donald E Ingber, By Drug Target Review
2026-10-07T14:00:00
Sponsored by WuXi AppTec
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud